|
18 Aug 2022 |
Immedica Pharma AB submits Marketing Authorisation Application to the European Medicines Agency seeking approval of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D)
|
|
03 Aug 2022 |
Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
|
|
29 Jul 2022 |
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3
|
|
28 Jul 2022 |
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
|
|
27 Jul 2022 |
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
|
|
26 Jul 2022 |
LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union
|
|
19 Jul 2022 |
Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression
|
|
19 Jul 2022 |
Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development
|
|
19 Jul 2022 |
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
|
|
14 Jul 2022 |
Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia
|
|
12 Jul 2022 |
Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at International Society for Thrombosis and Haemostasis Congress
|
|
12 Jul 2022 |
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
|
|
07 Jul 2022 |
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
|
|
07 Jul 2022 |
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
|
|
02 Jul 2022 |
Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED
|
|
02 Jul 2022 |
Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder
|
|
29 Jun 2022 |
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
|
|
29 Jun 2022 |
Endevica Reports the U.S. FDA Accepted Its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin‐4 Antagonist Peptide
|
|
28 Jun 2022 |
Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD
|
|
28 Jun 2022 |
Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease
|
|
17 Jun 2022 |
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome
|
|
15 Jun 2022 |
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
|
|
13 Jun 2022 |
Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
|
|
11 Jun 2022 |
Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)
|
|
10 Jun 2022 |
Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
|
